Value in Health Care

A summary of an ICER cost-effectiveness analysis published in JMCP found that despite incremental clinical benefits, biologics used to treat asthma have low long-term value for money.

A systematic review published in JMCP demonstrates that while life expectancy in HIV patients has increased, there is an increased incidence of age- and ART-associated comorbidities. This has important implications for future cost effectiveness analysis.

A systematic review published in JMCP demonstrates that while life expectancy in HIV patients has increased, there is an increased incidence of age- and ART-associated comorbidities. This has important implications for future cost effectiveness analysis.

Genomic testing technology is rapidly evolving, but these test are costly and analytically complex. This article, published in JMCP, suggests a standardized method for the development and application of clinically relevant genomic testing.

Genomic testing technology is rapidly evolving, but these test are costly and analytically complex. This article, published in the JMCP, suggests a standardized method for the development and application of clinically relevant genomic testing.

AMCP supports the use of value frameworks as a resource for determining the value of pharmaceuticals and other health technologies when the Frameworks are based on sound methods using good scientific evidence and economic models.

Collaboration and transparency in the development of cost-effectiveness models can increase the credibility and relevance of these models for local decision making, according to this JMCP article.

ICER's analysis of biologics used to treat asthma falls short of adequately addressing factors related to patients' health and quality of life, particularly those with severe, uncontrolled asthma, according to this JMCP article by the Asthma and Allergy Foundation of America's CEO.